Table 3. **Correlation between Airway Responsiveness to Methacholine and Indices that Variability of Peak Expiratory Flow Adjusted by Airway Geometric Factors**

Adjusting factors	Coefficient	p value	95% CI
Not adjusted	0.709	< 0.0001	0.607 , 0.788
Rrs ($cmH_2O/L/s$)	0.577	< 0.0001	0.444 , 0.686
FVC (L)	0.473	< 0.0001	0.322 , 0.602
FEV_1 (L)	0.532	< 0.0001	0.390 , 0.649
$\%FEV_1$ (%)	0.750	< 0.0001	0.659 , 0.819
Min PEF (L/min)	0.538	< 0.0001	0.398 , 0.654
Max PEF (L/min)	0.449	< 0.0001	0.293 , 0.581
Mean PEF (L/min)	0.495	< 0.0001	0.347 , 0.619

Definition of abbreviations: CI: confidence interval, Rrs: respiratory resistance, FVC: forced vital capacity, FEV_1: forced expiratory volume in one second, $\%FEV_1$: FEV_1 expressed as a percentage of the predicted value, PEF: peak expiratory flow, Min PEF: the lowest PEF over a week, Max PEF: the highest PEF over a week, Mean PEF: the mean value of the lowest and highest PEF, Min%Max PEF: the lowest PEF over a week, expressed as the percentage of the highest PEF



Figure 2. **Relationship between airway responsiveness and the lowest peak expiratory flow (PEF) during one week expressed as a percentage of the highest PEF (Min%Max PEF) normalized with or without forced volume in one second (FEV_1) percentage of the predicted value ($\%FEV_1$): a) Min%Max PEF; b) Min%Max PEF adjusted by $\%FEV_1$. The lines correspond to the fitted regression equation.**



Figure 3. **The nomogram to predict the degree of airway responsiveness in asthmatic subjects incorporating the variability of peak expiratory flow (Min%Max PEF) and forced expiratory volume in one second percentage of the predicted value ($\%FEV_1$). A cumulative provocative dose of methacholine causing a 100% increase in respiratory resistance (PD_{200}) was calculated by a correlation equation obtained from the regression analysis, as follows: $\log PD_{200}$=Min%Max PEF× $\%FEV_1$/1885-2.9.**

9, 10). Therefore, we sought to investigate the indices which correlate accurately with AHR by combining the index of airway lability with the parameters that represent airway caliber.

In fact, the current study demonstrated that $\%FEV_1$ was the airway geometric factor that correlated well with AHR, and adjusting Min%Max PEF for $\%FEV_1$ improved the correlation between Min%Max PEF and AHR. Airflow limitation in subjects with asthma may be reversible or fixed, and appears to represent a different dimension of asthma severity from airway lability. Several previous studies have shown that airflow limitation can be present with normal PEF variability and severe AHR (21-24). In addition, PEF measurements can underestimate the degree of airflow limitation, particularly as airflow limitation and gas trapping worsen (1). These are possible explanations for the fact that adjust-

ing the PEF variability for $\%FEV_1$ improved the relationship between Min%Max PEF and AHR. Actually, the improvement of this relationship by adjusting it by $\%FEV_1$ seemed to be more remarkable in the cases with higher airway responsiveness. By contrast, other geometric factors such as actual FEV_1 and Rrs values had significant but weak correlations with the methacholine threshold, and consequently the normalization of Min%Max PEF with these geometric factors did not improve the relationship between Min%Max PEF and AHR.

Min%Max PEF adjusted by $\%FEV_1$ appeared to be a convenient alternative to the index of AHR in asthmatic patients, and the resulting nomogram that could predict the degree of airway responsiveness may be useful for clinical asthma management. Because this proposed index correlated accurately with the degree of AHR, and it could be obtained by using conventional airway physiological parameters measured by spirometry and PEF monitoring. However, precise instruction is necessary so that patients can reliably measure PEF (1). In addition, although it has been demonstrated that PEF variability is the most useful index for reflecting AHR longitudinally in treated asthmatic patients, its correlations are not very strong (13). Thus, a longitudinal validation study is needed to clarify the utility of adjusting the measurements of Min%Max PEF by $\%FEV_1$ as a clinical index for the changes in AHR by pharmacologic interventions for asthma.

In conclusion, Min%Max PEF adjusted by $\%FEV_1$ showed a good correlation with the airway responsiveness measured by the inhalation challenge test, and may serve as a convenient alternative to the index of AHR in asthmatic patients.

Acknowledgement

We thank Mr. Brent Bell for reading this manuscript, and also thank Mr. Satoru Fukinbara for helping with statistical analysis.

References

1. National Heart Lung, and Blood Institute/World Health Organization. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention updated 2006. NIH Publication, Bethesda, 2006.
2. American Thoracic Society. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med **161**: 309-329, 2000.
3. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol **118**: 551-559, 2006.
4. Ichinose M, Takahashi H, Sugiura N, et al. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway caliber. Eur Respir J **15**: 248-253, 2000.
5. Gregg I, Nunn AJ. Peak expiratory flow in normal subjects. Br Med J **3**: 282-284, 1973.
6. Cockcroft DW. Therapy for airway inflammation in asthma. J Allergy Clin Immunol **87**: 914-919, 1991.
7. Sont JK, Willems LN, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL study group. Am J Respir Crit Care Med **159**: 1043-1051, 1999.
8. Nuijsink M, Hop WCJ, Sterk PJ, Duiverman EJ, de Jongste JC. Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomized controlled trial. Eur Respir J **30**: 457-466, 2007.
9. Benson MK. Bronchial hyperreactivity. Br J Dis Chest **69**: 227-239, 1975.
10. Britton J, Pavord I, Richards A, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: the importance of atopy and airway caliber. Eur Respir J **7**: 881-887, 1994.
11. Ryan G, Latimer KM, Dolovich J, Hargreave FE. Bronchial responsiveness to histamine: relationship to diural variation of peak flow rate, improvement after bronchodilator, and airway caliber. Thorax **37**: 423-429, 1982.
12. Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? Am J Respir Crit Care Med **151**: 1320-1325, 1995.
13. Douma WR, Kerstjens HA, Ross CM, Koeter GH, Postma DS; The Dutch Chronic Non-Specific Lung Disease Study Group. Changes in peak expiratory flow indices as a proxy for changes in bronchial hyperresponsiveness. Eur Respir J **16**: 220-225, 2001.
14. Woolcock AJ. Use of corticosteroids in treatment of patients with asthma. J Allergy Clin Immunol **84**: 975-978, 1990.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis **136**: 225-244, 1987.
16. Takishima T, Hida W, Sasaki H, Suzuki S, Sasaki T. Direct writing recorder of the dose-response curves of the airway to methacholine. Chest **80**: 600-606, 1981.
17. Matsunaga K, Yanagisawa S, Ichikawa T, et al. Airway cytokine expression measured by means of protein array in exhaled breath condensate: Correlation with physiologic properties in asthmatic patients. J Allergy Clin Immunol **118**: 84-90, 2006.
18. American Thoracic Society. Standardization of spirometry-1994 update. Am J Respir Crit Care Med **152**: 1107-1136, 1995.
19. National Heart Lung, and Blood Institute. Statement on technical standards for peak flow meters. National Asthma Education Program, Expert Panel Report. 1990.
20. Dubois AB. Resistance to breathing. In: Handbook of Physiology, Section 3: Respiration. Vol 1. Fenn WO, Rahn H, Eds. American Physiologic Society, Washington, 1964: 451-462.
21. Ferguson AC. Persisting airway obstruction in asymptomatic children with asthma with normal peak expiratory flow rates. J Allergy Clin Immunol **82**: 19-22, 1988.
22. Paggiaro P, Moscato LG, Giannini D, et al. The Italian Working Group on the use of peak expiratory flow rate (PEFR) in asthma. Eur Respir Rev **14**: 438-443, 1993.
23. Saetta M, Thiene G, Crescioli S, Fabbri LM. Fetal asthma in a young patient with severe bronchial hyperresponsiveness but stable peak flow records. Eur Respir J **2**: 1008-1012, 1989.
24. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J **24**: 122-128, 2004.

ANTIOXIDANTS & REDOX SIGNALING
Volume 10, Number 4, 2008

DOI: 10.1089/ars.2007.1937

Forum Review

Oxidative and Nitrative Stress in Bronchial Asthma

HISATOSHI SUGIURA and MASAKAZU ICHINOSE

ABSTRACT

There has been a marked increase in the global prevalence, morbidity, and mortality of asthma, and its associated economic burden has also grown over the last 40 years. Approximately 300 million people worldwide currently have asthma, and its prevalence increases by 50% every decade. Airway inflammation is the most proximate cause of the recurrent episodes of airflow limitation in asthma. Recent research has revealed that numerous biologically active proinflammatory mediators are responsible for the pathogenesis of asthma. Among these mediators, there is increasing evidence that endogenous or exogenous reactive oxygen species (ROS) and reactive nitrogen species (RNS) are responsible for the airway inflammation of asthma. Many reports have shown that there is an excessive production of ROS and RNS in the airways of asthmatic individuals compared with healthy subjects. Excessively produced ROS and RNS have been reported to lead to airway inflammation, airway hyper-responsiveness, airway microvascular hyperpermeability, tissue injury, and remodeling in animal models and human studies. Although human lungs have a potent antioxidant system, excessive oxidative and nitrative stress leads to an imbalance of oxidants/antioxidants. This review describes the rapidly accruing data linking oxidative and nitrative events to the pathogenesis of bronchial asthma. *Antioxid. Redox Signal.* 10, 785–797.

INTRODUCTION

In various inflammatory lung diseases, reactive oxygen species (ROS) and reactive nitrogen species (RNS), including superoxide anion, hydroxyl radicals, hydrogen peroxide, hypochlorous acid, ozone, and peroxynitrite, have been reported to play a pivotal role in the airway inflammation and pathogenesis (58, 84, 111). Among the inflammatory lung diseases, especially in bronchial asthma, oxidative and nitrative stress has been shown to be related to the pathogenesis (4, 9, 85). Oxidant generation is part of the normal metabolism of many types of cells and is critical for cell homeostasis. Although the lung has a well-developed antioxidant system to protect itself against exposure to endogenous or exogenous noxious oxidants (59, 86), excessively produced ROS and RNS can still cause inflammation in the lungs.

Asthma is a chronic inflammatory disease of the airways in which various resident and migrated cell-derived molecules play a role (20, 26). Many experimental and clinical data suggest that an imbalance between oxidants and antioxidants causes the airway inflammation and airway hyper-responsiveness that are major features of asthma (6, 13, 15). In animal models, allergen- (105) and ozone-induced (106) airway inflammation and airway hyper-responsiveness are largely modified by inhibitors of the synthesis of reactive oxygen and related species or by scavengers of radical species, supporting this hypothesis. Superoxide anion (O_2^-) may also be exaggerated in asthmatic airways via the upregulation of xanthine oxidase (XO) in microvascular endothelial cells (44) and NADPH oxidase in the infiltrated eosinophils (96). These results suggest that ROS may be related to the pathophysiology of bronchial asthma.

In addition, nitric oxide (NO) production is increased in asthmatic airways, possibly via the inducible type of NO synthase (iNOS) (33, 47), and steroid treatment reduces the NO generation (91). NO rapidly reacts with superoxide anion which is released from inflammatory cells, including eosinophils, re-

Third Department of Internal Medicine, Wakayama Medical University School of Medicine, Wakayama City, Wakayama, Japan.

sulting in the formation of the highly proinflammatory molecule, peroxynitrite (10, 82). In addition, since RNS, including peroxynitrite, cause tissue injury in a variety of organs, nitrative stress may be partly responsible for the airway inflammation in asthmatic patients.

This review describes the pathophysiological mechanisms and the clinical relevance of ROS and RNS in bronchial asthma. The role of ROS and RNS on airway remodeling observed in asthmatic airways is described. Furthermore, this review will examine the relationship between oxidative/nitrative stress and the refractoriness to steroids in refractory asthma.

ROS AND BRONCHIAL ASTHMA

Endogenous oxidants and bronchial asthma

In asthmatic airways, infiltrated inflammatory cells into the airways including eosinophils, neutrophils, and mast cells produce many oxidants by various stimuli (53, 76, 96). In particular, prominent eosinophil infiltration is observed in airways of asthmatic patients. Eosinophils are thought to injure the airway tissues by secreting proteins from its granules, including eosinophil cationic protein, major basic protein, and oxidants (24). It has been reported that eosinophils are stimulated by platelet activating factor (PAF) and injure epithelial cells in the presence of halogen atoms such as chloride and bromide (9). In addition, eosinophils, like neutrophils, have NADPH oxidase (24). In a previous study, eosinophils from asthmatic patients produced more superoxide anion than those from healthy subjects, suggesting that eosinophils from asthmatic patients may be primed by unknown stimuli (94). Moreover, macrophages (21) and neutrophils (25) from asthmatic patients are also reported to produce more oxidants than those from healthy subjects. In many animal asthmatic models, greater than normal amounts of endogenous ROS and RNS were produced (12, 17, 63, 87, 120). These results suggest that the production of ROS and RNS is upregulated in the airways of asthma, causing airway inflammation and hyper-responsiveness in bronchial asthma.

Exogenous oxidants and bronchial asthma

The lungs receive exogenous oxidative stress because of their exposure to the atmosphere. In a guinea pig model, exogenously administered ozone caused injury to epithelial cells, induced the infiltration of inflammatory cells into airway walls, and caused airway hyper-responsiveness (39), which resembled the pathophysiology of asthmatic airways. In this model, various possibilities were raised to explain the mechanism by which exogenously administered ozone induced the airway inflammation and hyper-responsiveness. First, ozone injures epithelial cells. Epithelial cells have neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) which catalyzes substance P (SP) and bradykinin (BK). SP and BK induce airway microvascular hyperpermeability (116) and smooth muscle contraction (109). The breakdown of NEP and ACE may prolong the survival of tachykinins, leading to the neurogenic inflammation observed in the airways of asthma. This hypothesis is supported by the finding that the levels are upregulated in the airways of asthmatic patients compared with healthy subjects (18, 19). In a guinea pig model of ozone-induced airway hyper-responsiveness, it was reported that ozone stimulated the release of histamine, prostaglandins, leukotrien B_4 (LTB_4), and thromboxane B_2 (TxB_2) (55). These mediators can induce bronchoconstriction and induce the infiltration of inflammatory cells into the airways (16). Cigarette smoke contains huge amounts of oxygen radicals and nitrogen species (83). It is a well-known fact that cigarette smoke worsens the airway inflammation and hyper-responsiveness in healthy subjects and asthmatic patients (74). The inhalation of exogenous oxidants may stimulate the inflammatory cells and worsen the airway inflammation in the airways of bronchial asthma.

Effect of oxidants on resident cells in lungs

Epithelial cells. Injury and shedding of epithelial cells are observed in the airways of asthmatic patients (26). These pathophysiological changes of epithelial cells are mediated by various noxious agents. Epithelial cells are exposed to exogenous oxidants and endogenous oxidants derived from infiltrated inflammatory cells, and are therefore thought to have the most frequent opportunities to receive oxidative stress. In fact, when eosinophils were stimulated by PAF, they injured epithelial cells *in vitro* (118). Since this type of injury was suppressed by catalase, hydrogen peroxide was responsible for this eosinophil-mediated epithelial cell injury (118). Once epithelial cells are injured, NEP and ACE are inactivated as described above. Furthermore, epithelial cells secrete much prostaglandin E2 (PGE_2) which has bronchodilatory action (36). The loss of epithelial cells by oxidative stress can stimulate airway smooth muscle cell contraction through the above-mentioned mechanisms. This epithelial cell injury leads to the loss of the barrier function. As a result of this loss, it is easy for various antigens and stimuli to achieve access to the airway tissue and thereby worsen the airway inflammation in asthmatic patients.

Airway smooth muscle cells. When 10^{-4}–10^{-3} *M* hydrogen peroxide is administered to the trachea of guinea pig, airway smooth muscle contraction is observed (88). This contraction is augmented when the epithelial cells are removed, suggesting that hydrogen peroxide-mediated airway smooth muscle cell contraction is related to the inactivation of relaxant factors such as prostaglandins derived from epithelial cells (36, 88). Since in asthmatic airways, there is shedding of epithelial cells, the contractile effect of endogenous or exogenous hydrogen peroxide in airway smooth muscle cells might be enhanced in asthmatic individuals.

Secretary cells. Inhalation of ozone induces excessive mucus secretion from secretary glands and goblet cells in the trachea of sheep (80). This hypersecretion is inhibited by cyclooxigenase (COX) inhibitors, suggesting that ozone could stimulate COX activity and the products of COX could be related to this excessive secretion. Furthermore, superoxide anion stimulates the production of mucin-like glycoproteins by airway epithelial cells through COX pathways (2). These results suggest that oxidants enhance mucus secretion in epithelial cells. The excessive secretion observed in the airways of asthmatic patients may be due to this oxidant-mediated COX activation.

Endothelial cells. Superoxide anion generated by the xanthine-xanthine oxidase system injures endothelial cells and enhances microvascular permeability *in vivo* (60). The amount of superoxide anion production shows a good correlation with the albumin in bronchoalveolar lavage fluid (BALf) from antigen-challenged asthmatic patients, suggesting that oxidants may cause the extravasation of serum in asthmatic airways (92). Recently, we showed that endogenous NO, superoxide anion, and peroxynitrite could augment the microvascular permeability during the late allergic response in guinea pigs (105). Each inhibitor or scavenger inhibited the microvascular hyperpermeability during the late allergic response (Fig. 1). In the airways of asthmatic patients, especially during exacerbations of bronchial asthma, marked edema of the airways was observed (48, 68, 69). Because excessive production of oxidants occurs in the airways of asthmatic patients during exacerbations, oxidants may be involved in the formation of airway wall edema.

Inflammatory cells. Oxidants are reported to have various effects on inflammatory cells. When inflammatory cells are exposed to oxidants, chemotactic factors are released from them through the arachidonic cascade (79). Moreover, when mast cells are exposed to oxidants, the release of histamine and serotonin is significantly increased (78). These mediators are related to the pathogenesis of bronchial asthma, and oxidants may be related to the inflammation of airways through this mechanism.

Other cells. ROS can oxidize the lipid membrane of many types of cells and activate the arachidonic cascade. The oxidation of the lipid membrane by oxidants can produce prostaglandins and leukotrienes (107). These products can contract airway smooth muscle cells, augment the chemotaxis of inflammatory cells toward inflammatory sites, and enhance the extravasation of serum. Another report showed that oxidants can suppress the function of β-adrenergic receptors (52), which may enhance smooth muscle contraction. There is increasing evidence that ROS can activate the DNA binding capacity of nucleus factor kappa B (NF-kB) which mediates various proinflammatory cytokines, adhesion molecules, and chemokines (5, 7, 93). NF-kB can control the expression of various proinflammatory mediators. These mediators are thought to be important in the inflammation of airways in asthmatic patients. Therefore, the suppression or depletion of oxidants by specific inhibitors or scavengers may be a potent therapeutic target for the suppression of airway inflammation in asthmatic patients in the future.

Antioxidant system in lungs and bronchial asthma

Since the lungs are exposed to various types of oxidative stress, both endogenous and exogenous, the antioxidant system is well developed in lungs. Table 1 shows the antioxidant system in human lungs. There is increasing evidence that there are alterations of the antioxidant capacity in asthmatic individuals



FIG. 1. Effects of nitric oxide synthase (NOS) inhibitor, xanthine oxidase (XO) inhibitor, and peroxynitrite scavenger on airway microvascular permeability during late allergic response (LAR). *Vertical axes* showed percentages of leaky microvasculature in trachea of guinea pigs. The NOS inhibitor, N^G-nitro-L-arginine methyl ester (L-NAME), significantly suppressed the microvascular permeability during LAR [(**A**) *open bar*: vehicle-treated saline-exposed animals; *closed bar*: inactive enantiomar, N^G-nitro-D-arginine methyl ester (D-NAME)-treated antigen-challenged animals; *hatched bar*: L-NAME-treated antigen challenged animals]. The XO inhibitor, {4-amino-6-hydroxypyrazolo(3,4-d)pyrimidine}(AHPP), significantly suppressed the microvascular permeability during LAR [(**B**), *open bar*: vehicle-treated saline-exposed animals; *closed bar*: vehicle-treated antigen-challenged animals; *hatched bar*: AHPP-treated antigen challenged animals]. The peroxynitrite scavenger, ebselen, significantly suppressed the microvascular permeability during LAR [(**C**) *open bar*: vehicle-treated saline-exposed animals; *closed bar*: vehicle-treated antigen-challenged animals; *hatched bar*: ebselen-treated antigen challenged animals). $*p < 0.05$, $**p < 0.01$ compared with vehicle-treated saline-exposed group. $+p < 0.05$ compared with each inhibitor or scavenger-treated antigen-challenged group. Excerpted with permission Sugiura H, Ichinose M, Oyake T *et al. Am J Respir Crit Care Med* 1999; 160: 663–671. Copyright 1999 American Thoracic Society.

TABLE 1. ANTIOXIDANTS IN HUMAN LUNGS

Antioxidants	*Localization*
Cu, Zn-superoxide dismutase	Cytosol
Mn-superoxide dismutase	Mitochondria
Extracellular-superoxide dismutase	Epithelial lining fluid
Catalase	Cytosol, Alveolar space
Glutathione	Cytosol, Epithelial lining fluid
Glutathione peroxidase	Cytosol
Heme oxygenase-1, -2	Cytosol
Ascorbic acid	Extracellular
α-Tocophenol	Cell membrane
β-Carotene	Cell membrane

as compared with healthy subjects. Additionally, there are discrepancies in the expression of antioxidants in bronchial asthma. For instance, the expression of some antioxidants such as GSH and heme oxygenase was reported to be increased in bronchial asthmatic patients compared with healthy subjects, whereas other antioxidants such as SOD and glutathione peroxidase were decreased (84). The reasons for such discrepancies have not been elucidated. The relationship between antioxidant and bronchial asthma is reviewed in the following section.

Glutathione (GSH). GSH has an SH residue and reacts with oxygen radicals. GSH is also a low molecular weight, water-soluble radical scavenger, and a high concentration of GSH ($\sim$500 μM) exists in the epithelial lining fluid of the airways (14). The ratio of GSSG, the oxidized form of GSH, to 2GSH (GSSG/2GSH) can serve as a good indicator of the cellular redox state (77, 84). This ratio in GSH may be determined by the rates of hydrogen peroxide reduction by glutathione peroxidase and GSSG reduction by glutathione peroxidase (84). Thus, antioxidant enzymes play a critical role in the maintenance of the cellular reductive potential. In the airways of asthmatic patients, the levels of GSH are increased in BALf, suggesting that GSH production may be upregulated to protect the lungs from excessive oxidative stress in asthmatic patients (99). Because excessive oxidative stress enhances the airway inflammation, GSH could be a therapeutic target for bronchial asthma. A previous report showed that inhalation of GSH using an ultranebulizer induced bronchoconstriction in mild asthmatic patients; the low pH (3.0) of the GSH solution caused bronchoconstriction in mild asthmatics (62). The effect of GSH on asthmatic patients is not well known using other routes of GSH administration.

Superoxide dismutase (SOD). SOD is present in essentially every cell in the body and has been shown to play an important role in protecting cells and tissues against superoxide anion (66, 67). This antioxidant enzyme decomposes superoxide anion into hydrogen peroxide and oxygen as shown in the following equation:

$$2O_2^- + 2H^+ \rightarrow H_2O_2 + O_2$$

Three types of SODs have been reported (84). All the forms of SODs act by a common mechanism of dismutation of superoxide anion to the less potent hydrogen peroxide. One of the three forms of SODs is Cu,ZnSOD (66, 84). Its molecular weight is 17–28 kDa and it is mainly located in the cytosol. In lungs, it is localized in the bronchial and alveolar epithelium, macrophages, fibroblasts, and pneumocytes. Another form of SOD is MnSOD (84). The molecular weight of this form of SOD is 88 kDa and it is mainly located in mitochondria. It is localized in bronchial epithelium, macrophages, neutrophils, endothelial cells, vascular smooth muscle cells, and pneumocytes. The other form of SOD is an extra-cellular SOD (EC-SOD) (38). Its molecular weight is 135 kDa and it is abundantly present in blood vessels and the airways. It is a secretory, tetrameric glycoprotein and requires Cu and Zn for its activity. The expression of EC-SOD is induced by interferon-γ and depressed by tumor necrosis factor (TNF-α), transforming growth factor-β (TGF-β), and interleukin-1α (IL-1α) in fibroblasts (61). EC-SOD has also been found to be expressed by bronchial epithelial cells, type II pneumocytes, endothelial cells, and alveolar mecrophages (102). Our previous study showed that superoxide anion can cause airway hyper-responsiveness in an animal model (46). Intratracheal administration of xanthine-xanthine oxidase induces airway hyper-responsiveness in cat (46). This airway hyper-responsiveness was suppressed by pretreatment with Cu,ZnSOD, suggesting that the generation of superoxide anion is associated with the formation of airway hyper-responsiveness, which is a major feature of bronchial asthma (8). We also previously showed that exposure to ozone-induced airway hyper-responsiveness to methacholine and SOD reversed the increased airway hyper-responsiveness in cat (106), suggesting that superoxide anion is related to the ozone-induced airway hyper-responsiveness. A previous study showed that the activity of SOD was decreased in the epithelial cells from asthmatic patients compared with healthy subjects (100). Furthermore, the activity of SOD in the BALf from asthmatic patients was decreased compared with healthy subjects (100). The decreased SOD activity may prolong the survival of superoxide anion in the lung tissues. Because superoxide can induce injury of the airway epithelial cells and airway microvascular hyperpermeability, the decreased SOD activity may be associated with the airway inflammation and formation of hyper-responsiveness in asthmatic patients.

Catalase. Catalase is a homotetrameric protein and has a high molecular weight (240 kDa). This antioxidant enzyme decomposes hydrogen peroxide into water and oxygen as shown in the following equation (32):

$$2H_2O_2 \rightarrow 2H_2O + O_2$$

Catalase is ubiquitous in most animal cells. Catalase is located in peroxisomes and in the cytosol and is specially localized in type II pneumocytes and alveolar macrophages (49). A high concentration of catalase exists in the epithelial lining fluid and it is thought to play a protective role against oxidative stress in the lungs (31). When sensitized sheep were exposed to antigen, airway hyper-responsiveness to carbacol was observed. Pretreatment with catalase suppressed the increased airway hyperresponsiveness, suggesting that hydrogen peroxide plays a role in the airway hyper-responsiveness in asthma and catalase may protect against oxidant-induced airway hyper-responsiveness (54).

Glutathione peroxidase. Glutathione peroxidases are a family of selenium-dependent and -independent antioxidant enzymes. These antioxidant enzymes are divided into two forms, cellular and extracellular. Glutathione peroxidase is a 85 kDa protein with a tetrameric structure. It requires four atoms of selenium bound as seleno-cycteine moieties which confer catalytic activity. Glutathione peroxidase reduces hydrogen peroxide to water in the presence of GSH. Glutathione peroxidase has four isoforms. Three are selenium-dependent glutathione peroxidases and the other one is selenium independent. These glutathione peroxidases have been identified in a variety of cells (73) and are ubiquitously present in the cytosol. In asthmatic patients, the levels of glutathione peroxidase in blood are decreased compared to healthy subjects (30). There is increasing evidence that reactive nitrogen species including peroxynitrite are associated with the pathophysiology of bronchial asthma (41, 89). Because selenium-related antioxidants are powerful scavengers of peroxynitrite, glutathione peroxidase may reduce the inflammation of airways in asthmatic patients (98).

Heme oxygenase. Heme oxygenase is a member of the heat-shock protein family that catalyses the degradation of the heme molecule into biliverdin in a reaction that generates carbon monoxide and iron (113). This antioxidant enzyme has cytoprotective effects against oxidative stress. It has been reported that heme oxygenase knockout mice were markedly sensitive to oxidative stress (81). In an asthmatic model, heme oxygenase-1 induced by repeated administration of hemin suppressed the inflammation of the airways (114). The carbon monoxide concentration in the exhaled air from asthmatic patients is significantly elevated compared with healthy subjects (119), suggesting that heme oxygenase may have a protective effect against the oxidative stress in bronchial asthma.

Ascorbic acid. Ascorbic acid is a low molecular weight and water-soluble radical scavenger. Administration of ascorbic acid to asthmatic patients is reported to improve their airway hyper-responsiveness to methacholine and partially block exercise-induced bronchoconstriction (71).

Sources of ROS in lungs

Recruited inflammatory cells and lung resident cells including epithelial cells can produce oxidants. The univalent reaction of oxygen to superoxide anion is the most important step in the production of oxidants. Three major sources of superoxide anion have been identified as follows.

NADPH oxidase system. The generation of superoxide anion is mediated by NADPH as an electron donor in the one-electron reduction of oxygen to produce superoxide anion. NADPH oxidase is a multicomponent enzyme complex, part of which is located in the plasma membrane. Cell fractionation experiments have shown that the dormant oxidase is located in the plasma membrane and that it requires a cytosolic component for activation. The plasma membrane components include a 99 kDa glycosylated subunit and a 22 kDa nonglycosylated subunit. Together, the two subunits are tightly associated and contain a heme group, likely bound to the 22 kDa subunit. These two subunits and heme act as a unit to form the terminal component of the NADPH oxidase, since it directly reduces oxygen to superoxide anion. Another membrane component is a 67 kDa protein, likely a flavoprotein, requiring flavin adenine dinucleotide to function, and it probably acts to convert intracellular NADPH to NADP+. In addition to the membrane components, there are at least two, and probably more, cytoplasmic subunit components. A 47 kDa protein is phosphorylated following stimulation. The second is a 65 kDa protein which migrates from the cytosol to the plasma and phagolysosomal membranes following NADPH activation. Because eosinophils and neutrophils from asthmatic patients can produce more superoxide anion compared to those of healthy subjects (25, 94), NADPH oxidase in asthmatic subjects may be activated.

Xanthine oxidase. Xanthine oxidoreductase (XOR), first identified a century ago in milk, is a highly conserved member of the molybdoenzyme family. XOR has two interconvertible forms, xanthine dehydrogenase (XDH) and xanthine oxidase (XO). Both forms catalyze the conversion of hypoxanthine to xanthine and xanthine to uric acid (UA), the terminal two reactions of the purine degradation pathway. Basal expression of the XOR gene is mediated by several transcription factors including C/EBP, ETS-1, AP-1, AP-2, and TF-IID (115). Although the basal expression of XOR is low, a variety of factors including hypoxia, lipopolysaccharide (LPS), IFN-γ, IL-1, IL-6, TNF-α, and steroids upregulate the transcription (27). In an asthmatic model, the XOR activity was upregulated in the lung during the late allergic response phase (105). Moreover, an XOR inhibitor, {4-amino-6-hydroxypyrazolo(3,4-d)pyrimidine}(AHPP), suppressed allergen-induced microvascular hyperpermeability during LAR, suggesting that XOR may be associated with the extravasation induced by allergen challenge.

Mitochondrial respiration chain. The third major pathway for the generation of superoxide anion is the mitochondrial respiration chain. Mitochondrial superoxide anion can be generated from several sites in the respiration chain. The matrix side of the organelle associated with complex I, complex III, and the Q pool can generate superoxide anion in mitochondria. Superoxide may have a direct interaction with some

targets such as aconitase that may contribute to cell signaling through the release of iron from the enzyme. In bronchial asthma, the role of mitochondrial superoxide anion has not been well clarified. Because eosinophils from asthmatic patients can generate more superoxide anion than those from healthy subjects, the generation of superoxide anion from mitochondrion may be upregulated.

RNS AND BRONCHIAL ASTHMA

NO in the respiratory system

NO has a variety of physiological effects in mammalian cells (43, 72). In the respiratory system, endogenous NO plays a key role in the physiological regulation of the airway function. NO and related compounds are produced by a wide variety of residential and inflammatory cells in the respiratory system. NO is generated via a five-electron oxidation of a terminal guanidinium nitrogen on the amino acid L-arginine. The reaction is both oxygen- and NADPH-dependent and yields the coproduct L-citrulline. This reaction is catalyzed by three isoforms of NO synthase (NOS). Neural NOS (NOS-I or nNOS) and endothelial NOS (NOS-III or eNOS) are both the constitutive type of NOS. The inducible type of NOS (NOS-II or iNOS) is upregulated by various cytokines, such as TNF-α, IFN-γ, and IL-1β, and can generate more NO compared with the constitutive type of NOS. The NO-generating cell types in lungs are listed in Table 2. In inflammatory sites, superoxide anion can be generated at the same time. It has been reported that NO reacts with superoxide anion very rapidly ($k = 6.7 \times 10^9\ M^{-1}S^{-1}$) and forms peroxynitrite (10, 82). RNS are also formed via the H2O2/peroxidase-dependent nitrite oxidation pathway (28). These RNS cause airway inflammation (105), namely the activation of matrix metalloproteinase (MMP) (75), and an enhancement of the production of the proinflammatory cytokine TNF-α (65). Therefore, RNS may be involved in the pathophysiology of the inflammatory process of bronchial asthma.

TABLE 2. LOCALIZATION OF NITRIC OXIDE SYNTHASES (NOS) IN HUMAN LUNGS

Isoforms	*Localization*
NOS I	Neurons (ganglion, trachea, and bronchus)
	Airway epithelial cells
	Neutrophils
NOS II	Macrophages
	Airway epithelial cells
	Type II pneumocytes
	Endothelial cells
	Fibroblasts
	Vascular smooth muscle cells
	Neutrophils
	Eosinophils
	Mast cells
NOS III	Endothelial cells
	Airway epithelial cells
	Platelets

Role of NOS in bronchial asthma

NO derived from cNOS plays a physiological role in the respiratory system. NO derived from NOS I is thought to partly regulate the airway smooth muscle tone. In the pulmonary vasculature, the role of NO from NOS III has been controversial. Conversely, NO derived from NOS II is thought to play a critical role in the airway inflammation. The role of each NOS is reviewed in this section.

NOS I. The inhibitory nonadrenergic noncholinergic (iNANC) nerve is the only neural bronchodilator system in human airways, where its bronchodilatory function has been demonstrated *in vitro* by electrical field stimulation (EFS) (108), as well as *in vivo* by reflex stimulation (42). The neurotransmitter of this nervous system has been suggested to be vasoactive intestinal peptide (VIP) or other related peptides in several species, since these peptides have a potent bronchodilatory action. NO has also been recognized as a transmitter of iNANC nerves distributed in various organs (110), including airways (110), by functional studies using inhibitors for NOS. Histochemically, colocalization of nicotinamide adenine dinucleotide phosphate (NADPH)-diaphorase activity, a marker for the nervous system, was used to demonstrate the existence of NOS I in guinea pig airways. In guinea pig airways, both NO and VIP have been reported to functionally mediate iNANC relaxation (57). In human airways, NO is thought to mainly mediate iNANC responses (11). This bronchodilatory function of iNANC may be impaired in asthmatic airways. According to our previous report, the bronchodilatory function of iNANC by EFS in the tracheas from antigen-challenged guinea pigs was impaired, compared to control animals (70). Furthermore, the impaired bronchodilatory function of iNANC was restored by pretreatment with SOD, suggesting that excessively produced superoxide anion inactivates the bronchodilatory action of NO derived from NOS I (70).

NOS III. Some studies showed that NO derived from NOS III regulated the pulmonary vascular tone in various species (34). These findings are based on studies using NOS inhibitors. However, other studies showed that even the highest doses of NOS inhibitor did not show any vasoconstriction in pulmonary vasculatures. In human, Stamler *et al.* reported that L-NMMA caused pulmonary vasoconstriction in healthy human volunteers (101). However, the effect of NOS inhibitors was more dominant in the systemic circulation than in the pulmonary circulation (34). Data obtained from *in vitro* human preparations are also inconclusive (23). Taken together, the role of NO derived from NOS III has not been fully elucidated yet.

NOS II. In various inflammatory lung diseases including asthma, chronic obstructive pulmonary diseases (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, iNOS is reported to be upregulated in the airways and lungs. iNOS gene is stimulated by various proinflammatory cytokines. In asthmatic individuals, increased levels of exhaled NO have been found (47). In asthmatic airways, the expression of iNOS was enhanced in pathological examinations (33). Increased expression of iNOS was seen in infiltrated inflammatory cells and macrophages, and the increased expression was corticosteroid

sensitive (91). Because steroids can suppress both iNOS expression and the exhaled NO levels, the increasing NO levels in expired air from asthmatic patients is thought to be derived from iNOS. This result is supported by the fact that inhalation of a relatively specific inhibitor of iNOS, SC-51, reduced the expired NO levels in asthmatic individuals (35). We previously showed that iNOS immunopositive cell counts in induced sputum had a significantly positive correlation with the NO levels in exhaled air in asthmatic patients (Fig. 2) (41). These results suggest that the enhanced iNOS expression in the airways of asthmatic patients is responsible for the increased NO levels in expired air. According to previous studies, exhaled NO may reflect the clinical control of asthma, particularly during exacerbations (64).

Nitrative stress and airway inflammation in bronchial asthma

Our previous report showed that nitrative stress could induce airway inflammation during the late allergic phase in an antigen-challenged guinea pig model (105). During the late phase, the NO levels in antigen-challenged animals significantly increased compared to control animals. A nonspecific NOS inhibitor, L-NAME, and the peroxynitrite scavenger, ebselen, inhibited the antigen-induced microvascular hyperpermeability, suggesting that nitrative stress may contribute to the airway inflammation in bronchial asthma. Moreover, exogenously administered peroxynitrite stimulated the release of toxic granules from eosinophils (95). In addition, because eosinophil cationic protein and major basic protein from eosinophils can cause tissue injury (22) and muscarinic 2 (M2) receptor dysfunction (56), RNS may be responsible for the airway inflammation in asthma through eosinophil activation.

Nitrative stress and airway hyper-responsiveness in bronchial asthma

To clarify the role of iNOS in the airway hyper-responsiveness in asthmatic airways, we investigated further by using an asthmatic mouse model. We showed that iNOS was upregulated after antigen challenge in sensitized mice (Fig. 3) (50). Furthermore, we showed that both pharmacological blockade of iNOS (50) and depletion of iNOS gene (51) also inhibited the antigen-induced airway hyper-responsiveness in mice. In iNOS knockout mice, nitrotyrosine formation, which is a footprint of RNS, was completely diminished. Furthermore, Sadeghi–Hashjin *et al.* showed that exogenously administered peroxynitrite induced airway hyper-responsiveness *in vivo* and *in vitro* (95). Taken together, nitrative stress appears to cause airway hyper-responsiveness in bronchial asthma. In humans, we reported that the exhaled NO level significantly correlated with the baseline FEV1 values in steroid naïve asthmatic patients (40). Treatment with inhaled corticosteroids was associated with a reduction in the NO levels in exhaled air and an improvement in FEV1 and airway hyper-responsiveness, suggesting that exhaled NO can serve as a marker of airway inflammation and is associated with the airway caliber and hyper-responsiveness induced by the airway inflammation.

Nitrative stress and airway remodeling in bronchial asthma

Excessive production of NO during inflammatory and immune processes leads to the formation of RNS including peroxynitrite and nitrogen dioxide (NO_2). These RNS are formed from NO and superoxide anion or via the H_2O_2/peroxidase-dependent nitrite oxidation pathway. In inflammatory condi-



FIG. 2. Immunocytostaining of the inducible type of nitric oxide synthase (iNOS) and nitrotyrosine. (**A**) Representative photographs of immunocytostaining of iNOS (*left panels*) and nitrotyrosine (*right panels*) from healthy (*upper panels*) and asthmatic subjects (*lower panels*) are shown. Relation of iNOS-positive cell counts to nitrotyrosine (NT)-positive cell counts in induced sputum from asthmatic subjects (**B**). R is correlation coefficient; the line and *p* value correspond to the fitted regression equation. Excerpted with permission Ichinose M, Sugiura H, Yamagata S *et al. Am J Respir Crit Care Med* 2000; 162: 701–706. Copyright 2000 American Thoracic Society.



FIG. 3. Inducible type of nitric oxide synthase (iNOS) expression during late phase allergic reaction in mice and effect of the specific iNOS inhibitor, 1,400 W, on airway hyper-responsiveness. (**A**) Immunoblot analysis of the expression of iNOS in airway tissue isolated from sensitized mice. Positive control: sample of mice macrophage lysates stimulated with interferon-γ (IFN-γ) and lipopolysaccharide (LPS); OVA: 24 h after ovalbumin (OVA) challenge; saline: 24 h after saline exposure. (**B**) Quantification of the intensity of the bands by densitometry. Lanes are the same as in (**A**). (**C**) Effect of 1,400 W on airway hyper-responsiveness after OVA challenge in sensitized mice. Airway responsiveness was assessed by means of airway opening pressure (Pao) measurement after intravenous methacholine (MCh) administration. $*p < 0.01$ compared with the saline-pretreated saline challenged mice. $+p < 0.05$ and $++p < 0.01$ compared with the saline-pretreated OVA-challenged mice. Each value indicates mean + SEM. *Open bars*: saline-pretreated saline-challenged; *filled bars*: saline-pretreated OVA-challenged; *hatched bars*: 1,400 W-pretreated OVA-challenged. Excerpted with permission, Koarai A, Ichinose M, Sugiura H *et al. Pulm Pharmacol Ther* 2000; 13: 267–275. Copyright 2000 Elsevier Ltd.

tions where superoxide anion is generated, NO is rapidly consumed by reacting with superoxide to produce highly reactive peroxynitrite. Peroxynitrite is an extremely powerful oxidant and is presumed to be largely responsible for many of the adverse effects of the excessive generation of NO. Excessive production of RNS causes tissue injury, lipid peroxidation, and nitration of tyrosine residues. Consistent with the role of this pathway in disease, excessive production of 3-nitrotyrosine has been observed in various inflammatory lung diseases, including bronchial asthma (33, 91, 103), COPD (37, 103), and IPF (90). Inflammatory processes are frequently accompanied by alterations in the tissue structure. Such alterations may result from tissue damage due to active proteases or toxic moieties released by inflammatory cells. In addition, mediators released at inflammatory sites are capable of directly altering the cell function, leading to tissue repair and remodeling. The production of RNS causes tissue injury, but whether RNS can affect tissue repair and remodeling remains unknown. Recently, we reported the effect of peroxynitrite on tissue remodeling by using a collagen gel contraction assay model mediated by human lung fibroblasts *in vitro* (104). As shown in Fig. 4, exogenously administered peroxynitrite augmented fibroblast-mediated collagen gel contraction in a dose-dependent manner. Peroxynitrite also stimulated the production of TGF-β_1, fibronectin, and vascular endothelial growth factor (VEGF), which are thought to play critical roles in lung tissue remodeling (104). Furthermore, treatment with peroxynitrite augmented the chemotaxis of fibroblasts toward fibronectin through augmenting the expression of integrins, which are receptors for fibronectin (104). The augmented collagen gel contraction, mediator production, and chemotaxis were reversed by treatment with neutralizing anti-TGF-β antibody (104). These results suggest that peroxynitrite or other RNS may cause tissue remodeling through TGF-β_1 activation. In fact, TGF-β_1 is a key mediator in a variety of physiological and pathological processes, including fibroblast repair responses. TGF-β



FIG. 4. Effect of authentic peroxynitrite on collagen gel contraction by human fetal lung fibroblasts (HFL-1). Fibroblasts were cast into three-dimensional collagen gels and floated in medium containing various concentrations of peroxynitrite. Gel size was measured daily. When the gel size becomes smaller, the fibroblast-mediated tissue remodeling is augmented. *Vertical axis*: gel size (% of initial size); *horizontal axis*: time. $**p < 0.01$; compared with the values of control. *Open circles*, control; *triangles*, 0.1 μM peroxynitrite; *squares*, 1 μM peroxynitrite; *filled circles*, 10 μM peroxynitrite. Excerpted with permission, Sugiura H, Liu X, Kobayashi T *et al. Am J Respir Cell Mol Biol* 2006; 34: 592–599. Copyright 2006 American Thoracic Society.

TABLE 3. OXIDATIVE AND NITRATIVE STRESS IN LUNG TISSUES

Target tissue and cells	*Effects of ROS and RNS*
Epithelial cells	Injury
	Proinflammatory mediators production
Mucus glands	Mucus hypersecretion
Airway micro vessels	Plasma leakage
	Edema
	Vasodilatation
	Neovascularization
Sensory nerves	Activation
Inhibitory nonadrenergic noncholinergic nerves	Inactivation
Fibroblasts	Activation
	Augmentation of migration
Airway smooth muscle cells	Contraction
Inflammatory cells	Mediator production and secretion
	MMP activation

ROS, reactive oxygen species; RNS, reactive nitrogen species; MMP, matrix metalloproteinase.

regulates the fibroblast migration, proliferation, differentiation, and production of matrix and soluble factors. In addition, TGF-β stimulates the fibroblast-mediated contraction of the extracellular matrix. Through these actions, TGF-β is believed to be a major regulator of tissue remodeling. Among the mediators induced by TGF-β are fibronectin (117) and VEGF (112). Fibronectin can form a provisional extracellular matrix following injury and is a potent chemoattractant for fibroblasts. VEGF is a multifunctional cytokine that stimulates endothelial cell mitogenesis and migration and modulates the endothelial permeability. The production of VEGF, therefore, could play a role in the neovascularization that characterizes tissue repair following injury. In fact, the production of these mediators was augmented in asthmatic airways and excessive extracellular matrix deposition was observed in the basement membrane in the airways of asthmatic patients (29). Therefore, nitrative stress may contribute to the formation of the airway remodeling observed in asthmatics, especially in refractory asthmatic patients.

NITRATIVE STRESS AND REFRACTORY ASTHMA

Asthma is a disorder characterized by chronic inflammation of the airways, airflow obstruction, and airway hyperreactivity. Most asthmatic patients are well controlled by low doses of anti-inflammatory agents with or without bronchodilators. However, 5–10% of asthmatic patients have more troublesome disease, reflected by a higher medication requirement to maintain good disease control or persistent symptoms and disease exacerbation, airflow obstruction, or low quality of life in spite of using high doses of steroids (3). To describe this subgroup of asthmatic patients with troublesome disease, the term "refractory asthma" has been used (3). It has been reported that individuals with refractory asthma are 15 times more likely to use emergency medical care than well-controlled asthmatic patients and are 20 times more likely to require hospital admission (97). Furthermore, these individuals with refractory asthma also have greater absenteeism from work on account of their



FIG. 5. Crosstalk between reactive oxygen species and reactive nitrogen species. Cat, catalase; Fe^{++}, ferrous ion; H_2O_2, hydrogen peroxide; MPO, myeloperoxidase; NO, nitric oxide; NO_2·, nitrogen dioxide radical, NO_2, nitrogen dioxide; OH·, hydroxyl radical; O_2^-, superoxide anion; $ONOO^-$, peroxynitrite, SODs, superoxide dismutases.

disease. However, there has been little information on the pathophysiological mechanisms responsible for refractory asthma. Understanding the differences in the airway inflammation between refractory and well-controlled asthma could therefore be important for determining the mechanisms responsible for refractory asthma. Recently, we investigated the differences in oxidative and nitrative stress among healthy subjects, well-controlled asthmatic subjects, and refractory asthmatic subjects. Oxidative stress and nitrative stress were enhanced in the refractory asthmatic group (unpublished data). Steroids have a number of anti-inflammatory actions, including the suppression of iNOS expression. In this study, steroids could not suppress iNOS expression or 3-nitrotyrosine formation in the sputum from patients with refractory asthma even at high doses. Recently, Ito and co-workers reported that peroxynitrite reduced the histone deacetylase 2 (HDAC 2) activity in epithelial cells through the nitration of tyrosine residues in HDAC 2 (45). A reduction of HDAC 2 activity could contribute to the worsening of inflammation through the excessive production of proinflammatory cytokines including IL-1β and IL-8 (1). They also showed that the HDAC 2 activity was decreased in asthmatic patients and patients with COPD (1). Inhibition of HDAC 2 was reported to interfere with glucocorticoid receptor-activated transcription (1). Taken together, it may be possible that an inactivation of HDAC 2 by excessive RNS occurs in refractory asthma. Moreover, since RNS may be associated with tissue remodeling as mentioned before, oxidative and nitrative stress may contribute to the refractoriness to steroid therapy in refractory asthmatic patients.

SUMMARY

The composite role of ROS and RNS in the lung pathology of asthma is shown in Table 3. Asthma is associated with increased levels of ROS and RNS due to the activation of infiltrated inflammatory cells and resident cells stimulated by proinflammatory mediators. Numerous reports have shown that oxidative and nitrative stress can cause airway inflammation and hyper-responsiveness which are the most important features of asthma. Because of excessive oxidative and nitrative stress, an imbalance of oxidants and antioxidants occurs in the airways of asthma. Interactions between ROS and RNS are summarized in Fig. 5. ROS and RNS may stimulate some transcription factor activities and change the transcription of proinflammatory cytokines. ROS and RNS appear to be related to the airway remodeling and refractoriness to steroids. Blockers or scavengers of ROS and RNS may become therapeutic targets in the future.

ACKNOWLEDGMENT

The authors thank Mr. B. Bell for reading the manuscript.

ABBREVIATIONS

ACE, angiotensin converting enzyme; BALf, bronchoalveolar lavage fluid; BK, bradykinin; COPD, chronic obstructive pulmonary disease; COX, cyclooxygenase; EFS, electrical field stimulation; GSH, glutathione; HDAC, histone diacetylase; HFL, human fetal lung fibroblast; IFN, interferon; IL, interleukin; iNANC, inhibitory nonadrenergic noncholinergic; IPF, idiopathic pulmonary fibrosis; LAR, late allergic response; LPS, lipopolysaccharide; LT, leukotrien; MCh, methacholine, MMP, matrix metalloproteinase; NEP, neutral endopeptidase; NF-kB, nucleus factor kappa B; NO, nitric oxide; NOS, nitric oxide synthase; NT, nitrotyrosine; OVA, ovalbumin; PAF, platelet activating factor; Pao, airway opening pressure, PG, prostaglandin; RNS, reactive nitrogen species; ROS, reactive oxygen species; SOD, superoxide dismutase; SP, substance P; TGF, transforming growth factor; TNF, tumor necrosis factor; Tx, thromboxane; UA, uric acid; VEGF, vasoactive endothelial growth factor; VIP, vasoactive intestinal peptide; XDH, xanthine dehydrogenase; XO, xanthine oxidase; XOR, xanthine oxide reductase.

REFERENCES

1. Adcock IM, Ford P, Barnes PJ, and Ito K. Epigenetics and airways disease. *Respir Res* 7: 21, 2006.
2. Adler KB, Holden Stauffer WJ, and Repine JE. Oxygen metabolites stimulate release of high molecular weight glycoconjugates by cell and organ cultures of rodent respiratory epithelium via an arachidonic acid dependent mechanism. *J Clin Invest* 85: 75–85, 1990.
3. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. *Am J Respir Crit Care Med* 162: 2341–2351, 2000.
4. Andreadis AA, Hazen SL, Comhair SA, and Erzurum SC. Oxidative and nitrosative events in asthma. *Free Radic Biol Med* 35: 213–225, 2003.
5. Baldwin Jr AS. The NF-κB and I-κB proteins: New discoveries and insights. *Annu Rev Immunol* 14: 649–681, 1996.
6. Barnes PJ. Reactive oxygen species and airway inflammation. *Free Radical Biol Med* 9: 235–243, 1990.
7. Barnes PJ, Chung KF, and Page CP. Inflammatory mediators of asthma: an update. *Pharmacol Rev* 50: 515–596, 1998.
8. Barnes PJ and Karin M. Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 336: 1066–1071, 1997.
9. Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. *J Allergy Clin Immunol* 83: 1013–1026, 1989.
10. Beckman JS, Beckman TW, Chen J, Marshall PA, and Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 87: 1620–1624, 1990.
11. Belvisi MG, Stretton CD, Miura M, Verleden GM, Tadjkarimi S, Yacoub MH, and Barnes PJ. Inhibitory NANC nerves in human tracheal smooth muscle: a quest for the neurotransmitter. *J Appl Physiol* 73: 2505–2510, 1992.
12. de Boer J, Meurs H, Flendrig L, Koopal M, and Zaagsma J. Role of nitric oxide and superoxide in allergen-induced airway hyperreactivity after the late asthmatic reaction in guinea-pigs. *Br J Pharmacol* 133: 1235–1242, 2001.
13. Bowler RP and Crapo JD. Oxidative stress in allergic respiratory diseases. *J Allergy Clin Immunol* 110: 349–356, 2002.
14. Cantin AM, North SL, Hubbard RC, and Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. *J Appl Physiol* 63: 152–157, 1987.
15. Caramori G and Papi A. Oxidants and asthma. *Thorax* 59: 170–173, 2004.
16. Carey MA, Germolec DR, Langenbach R, and Zeldin DC. Cyclooxygenase enzymes in allergic inflammation and asthma. *Prostaglandins Leukot Essent Fatty Acids* 69: 157–162, 2003.

17. Chang LY and Crapo JD. Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic. *Free Radic Biol Med* 33: 379–386, 2002.
18. Christiansen SC, Proud D, and Cochrane CG. Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. *J Clin Invest* 79: 188–197, 1987.
19. Christiansen SC, Proud D, Sarnoff RB, Juergens U, Cochrane CG, and Zuraw BL. Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge. *Am Rev Respir Dis* 145: 900–905, 1992.
20. Chung KF and Barnes PJ. Cytokines in asthma. *Thorax* 54: 825–857, 1999.
21. Cluzel M, Damon M, Chanez P, Bousquet J, Crastes de Paulet A, Michel FB, and Godard P. Enhanced alveolar cell luminol-dependent chemiluminescence in asthma. *J Allergy Clin Immunol* 80: 195–201, 1987.
22. Coyle AJ, Uchida D, Ackerman SJ, Mitzner W, and Irvin CG. Role of cationic proteins in the airway. Hyperresponsiveness due to airway inflammation. *Am J Respir Crit Care Med* 150: S63–71, 1994.
23. Cremona G, Wood AM, Hall LW, Bower EA, and Higenbottam T. Effect of inhibitors of nitric oxide release and action on vascular tone in isolated lungs of pig, sheep, dog and man. *J Physiol* 481: 185–195, 1994.
24. DeChatelet LR, Shirley PS, McPhail LC, Huntley CC, Muss HB, and Bass DA. Oxidation metabolism of the human eosinophil. *Blood* 50: 257–262, 1977.
25. Degenhart HJ, Raatgeep HC, Neijens HJ, and Kerrebjin KF. Oxygen radicals and their production by leukocytes from children with asthma and bronchial hyperresponsiveness. *Clin Resp Physiol* 22: 100–103, 1986.
26. Dunnill MS. The pathology of asthma with special reference to changes in the bronchial mucosa. *J Clin Pathol* 13: 27–33, 1960.
27. Dupont GP, Huecksteadt TP, Marshall BC, Ryan US, Michael JR, and Hoidal JR. Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells. *J Clin Invest* 89: 197–202, 1992.
28. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, and van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. *Nature* 391: 393–397, 1998.
29. Elias JA, Zhu Z, Chupp G, and Homer RJ. Airway remodeling in asthma. *J Clin Invest* 104: 1001–1006, 1999.
30. Flatt A, Pearce N, Thomson CD, Sears MR, Robinson MF, and Beasley R. Reduced selenium in asthmatic subjects in New Zealand. *Thorax* 45: 95–99, 1990.
31. Flick MR, Milligan SA, Hoeffel JM, and Goldstein IM. Catalase prevents increased lung vascular permeability during air emboli in unanesthetized sheep. *J Appl Physiol* 64: 929–935, 1988.
32. Fridovich I and Freeman B. Antioxidant defenses in the lung. *Annu Rev Physiol* 48: 693–702, 1986.
33. Hamid Q, Springall DR, Riveros–Moreno V, Chanez P, Howarth P, Redington A, Bousquet J, Godard P, Holgate S, and Polak JM. Induction of nitric oxide synthase in asthma. *Lancet* 342: 1510–1513, 1993.
34. Hampl V and Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. *Physiol Rev* 80: 1337–1372, 2000.
35. Hansel TT, Kharitonov SA, Donnelly LE, Erin EM, Currie MG, Moore WM, Manning PT, Recker DP, and Barnes PJ. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. *FASEB J* 17: 1298–1300, 2003.
36. Henricks PA and Nijkamp FB. Reactive oxygen species as mediators in asthma. *Pulm Pharmacol Ther* 14: 409–420, 2001.
37. Hirano T, Yamagata T, Gohda M, Yamagata Y, Ichikawa T, Yanagisawa S, Ueshima K, Akamatsu K, Nakanishi M, Matsunaga K, Minakata Y, and Ichinose M. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. *Thorax* 61: 761–766, 2006.
38. Hjalmarsson K, Marklund SL, Engstrom A, and Edlund T. Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase. *Proc Natl Acad Sci USA* 84: 6340–6344, 1987.
39. Holbrook M, Gozzard N, James T, Higgs G, and Hughes B. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. *Br J Pharmacol* 118:1192–1200, 1996.
40. Ichinose M, Sugiura H, Yamagata S, Koarai A, and Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. *Am J Respir Crit Care Med* 162: 701–706, 2000.
41. Ichinose M, Inoue H, Miura M, and Takishima T. Nonadrenergic bronchodilation in normal subjects. *Am Rev Respir Dis* 138: 31–34, 1988.
42. Ichinose M, Takahashi T, Sugiura H, Endoh N, Miura M, Mashito Y, and Shirato K. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway calibre. *Eur Respir J* 15: 248–253, 2000.
43. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. *FASEB J* 3: 31–36, 1989.
44. Ikuta N, Sugiyama S, Takagi K, Satake T, and Ozawa T. Implication of oxygen radicals on airway hyperresponsiveness after ovalbumin challenge in guinea pigs. *Am Rev Respir Dis* 145: 561–565, 1992.
45. Ito K, Hanazawa T, Tomita K, Barnes PJ, and Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. *Biochem Biophys Res Commun* 315: 240–245, 2004.
46. Katsumata U, Miura M, Ichinose M, Kimura K, Takahashi T, Inoue H, and Takishima T. Oxygen radicals produce airway constriction and hyperresponsiveness in anesthetized cats. *Am Rev Respir Dis* 141: 1158–1161, 1990.
47. Kharitonov SA, Yates D, Robbins RA, Logan–Sinclair R, Shinebourne EA, and Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. *Lancet* 343: 133–135, 1994.
48. Kimura K, Inoue H, Ichinose M, Miura M, Katsumata U, Takahashi and T. Takishima T. Bradykinin causes airway hyperresponsiveness and enhances maximal airway narrowing. Role of microvascular leakage and airway edema. *Am Rev Respir Dis* 146: 1301–1305, 1992.
49. Kinnula VL, Crapo JD, and Raivio KO. Generation and disposal of reactive oxygen metabolites in the lung. *Lab Invest* 73: 3–19, 1995.
50. Koarai A, Ichinose M, Sugiura H, Yamagata S, Hattori T, and Shirato K. Allergic airway hyperresponsiveness and eosinophil infiltration is reduced by a selective iNOS inhibitor, 1400W, in mice. *Pulm Pharmacol Ther* 13: 267–275, 2000.
51. Koarai A, Ichinose M, Sugiura H, Tomaki M, Watanabe M, Yamagata S, Komaki Y, Shirato K, and Hattori T. iNOS depletion completely diminishes reactive nitrogen-species formation after an allergic response. *Eur Respir J* 20: 609–616, 2002.
52. Kramer K, Rademaker B, Rozendal WH, Timmerman H, and Bast A. Influence of lipid peroxidation on β-adrenoceptors. *FEBS Lett* 198: 80–94, 1986.
53. Lacy P, Abdel–Latif D, Steward M, Musat–Marcu S, Man SF, and Moqbel R. Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects. *J Immunol* 170: 2670–2679, 2003.
54. Lansing MW, Ahmed A, Cortes A, Sielczak MW, Wanner A, and Abraham WM. Oxygen radicals contribute to antigen-induced airway hyperresponsiveness in conscious sheep. *Am Rev Respir Dis* 147: 321–326, 1993.
55. Lee HKI and Murlas C. Ozone-induced bronchial hyperreactivity in guinea pigs in abolished by BW755C or FPL55712 but not by indomethacin. *Am Rev Respir Dis* 132: 1005–1009, 1985.
56. Lefort J, Nahori MA, Ruffie C, Vargaftig BB, and Pretolani M. *In vivo* neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs. *J Clin Invest* 97: 1117–1121, 1996.
57. Li CG and Rand MJ. Evidence that part of the NANC relaxant response of guinea-pig trachea to electrical field stimulation is mediated by nitric oxide. *Br J Pharmacol* 102: 91–94, 1991.
58. MacNee W. Oxidative stress and lung inflammation in airways disease. *Eur J Pharmacol* 429: 195–207, 2001.

59. MacNee W. Oxidants/antioxidants and COPD. *Chest* 117: 303S–317S, 2000.
60. del Maestro RF, Bjork J, and Arfors KE. Increase in microvascular permeability induced by enzymatically generated free radicals. I. *In vivo* study. *Microvasc Res* 22: 239–254, 1981.
61. Marklund SL. Regulation by cytokines of extracellular superoxide dismutase and other superoxide dismutase isoenzymes in fibroblasts. *J Biol Chem* 267: 6696–66701, 1992.
62. Marrades RM, Roca J, Barbera JA, de Jover L, MacNee W, and Rodriguez–Roisin R. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. *Am J Respir Crit Care Med* 156: 425–430, 1997.
63. Masini E, Bani D, Vannacci A, Pierpaoli S, Mannaioni PF, Comhair SA, Xu W, Muscoli C, Erzurum SC, and Salvemini D. Reduction of antigen-induced respiratory abnormalities and airway inflammation in sensitized guinea pigs by a superoxide dismutase mimetic. *Free Radic Biol Med* 39: 520–531, 2005.
64. Massaro F M, Gaston B, Kita D, Fanta C, Stamler J, and Drazen JM. Expired nitric oxide levels during treatment of acute asthma. *Am J Respir Crit Care Med* 152: 800–803, 1995.
65. Matata BM and Galinanes M. Peroxynitrite is an essential component of production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. *J Biol Chem* 277: 2330–2335, 2002.
66. McCord JM and Fridovich I. The utility of superoxide dismutase in studying free radical reactions. I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. *J Biol Chem* 244: 6056–6063, 1969.
67. McCord JM and Fridovich I. The utility of superoxide dismutase in studying free radical reactions. II. The mechanism of the mediation of cytochrome c reduction by a variety of electron carriers. *J Biol Chem* 245: 1374–1377, 1970.
68. McFadden ER Jr. Exertional dyspnea and cough as preludes to acute attacks of bronchial asthma. *N Engl J Med* 292: 555–559, 1975.
69. McFadden ER Jr and Gilbert IA. Asthma. *N Engl J Med* 327: 1928–1937, 1992.
70. Miura M, Yamauchi H, Ichinose M, Ohuchi Y, Kageyama N, Tomaki M, Endoh N, and Shirato K. Impairment of neural nitric oxide-mediated relaxation after antigen exposure in guinea pig airways *in vitro*. *Am J Respir Crit Care Med* 156: 217–222, 1997.
71. Mohsenin V, Dubois AB, and Douglas JS. Effect of ascorbic acid on responses to methacholine challenge in asthmatic subjects. *Am Rev Respir Dis* 127: 143–147, 1983.
72. Moncada S and Higgs A. The L-arginine-nitric oxide pathway. *N Engl J Med* 329: 2002–2012, 1993.
73. Mullenbach GT, Tabrizi A, Irvine BD, Bell GI, Tainer JA, and Hallewell RA. Selenocysteine's mechanism of incorporation and evolution revealed in cDNAs of three glutathione peroxidases. *Protein Eng* 2: 239–246, 1988.
74. O'Connor GT, Weiss ST, Tager IB, and Speizer FE. The effect of passive smoking on pulmonary function and nonspecific bronchial responsiveness in a population-based sample of children and young adults. *Am Rev Respir Dis* 135: 800–804, 1987.
75. Okamoto T, Akaike T, Nagano T, Miyajima S, Suga M, Andoh M, Ichimori K, and Maeda H. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. *Arch Biochem Biophys* 342: 261–274, 1997.
76. Paredi P, Kharitonov SA, and Barnes PJ. Analysis of expired air for oxidation products. *Am J Respir Crit Care Med*. 166: S31–37, 2002.
77. Park EM, Park YM, and Gwak YS. Oxidative damage in tissues of rats exposed to cigarette smoke. *Free Radic Biol Med* 25: 79–86, 1998.
78. Penden DB and Dailey L. Modulation of mast cell functions by *in vitro* ozone exposure. *Am J Physiol* 268: L902–L910, 1995.
79. Perez HD, Weksler BB, and Goldstein IM. Generation of a chemotactic lipid from arachidonic acid by exposure to a superoxide-generating system. *Inflammation* 4: 313–328, 1980.
80. Phipps RJ, Denas SM, Sielczak MW, and Wanner A. Effects of 0.5 ppm ozone on glycoprotein secretion, ion and water fluxes in sheep trachea. *J Appl Physiol* 60: 918–927, 1986.
81. Poss KD and Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. *Proc Natl Acad Sci USA* 94: 10925–10930, 1997.
82. Pryor WA and Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. *Am J Physiol* 268: L699–722, 1995.
83. Pryor WA and Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. *Ann NY Acad Sci* 686: 12–27, 1993.
84. Rahman I, Biswas SK, and Kode A. Oxidant and antioxidant balance in the airways and airway diseases. *Eur J Pharmacol* 533: 222–239, 2006.
85. Rahman I and MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. *Eur Respir J* 16: 534–554, 2000.
86. Rahman I. Regulation of glutathione in inflammation and chronic lung diseases. *Mutat Res* 579: 58–80, 2005.
87. Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, Yamamoto M, Kensler TW, Tuder RM, Georas SN, and Biswal S. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. *J Exp Med* 202: 47–59, 2005.
88. Rhoden KJ and Barnes PJ. Effect of hydrogen peroxide on guinea-pig tracheal smmoth muscle *in vitro*: role of cyclo-oxygenase and airway epithelium. *Br J Pharmacol* 98: 325–330, 1989.
89. Ricciardolo FL, Di Stefano A, Sabatini F, and Folkerts G. Reactive nitrogen species in the respiratory tract. *Eur J Pharmacol* 533: 240–252, 2006.
90. Saleh D, Ernst P, Lim S, Barnes PJ, and Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. *FASEB J* 12: 929–937, 1998.
91. Saleh D, Barnes PJ, and Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 155: 1763–1769, 1997.
92. Sanders SP, Zweier JL, Harrison SJ, Trush MA, Rembish SJ, and Liu MC. Spontaneous oxygen radical production at sites of antigen challenge in allergic subjects. *Am J Respir Crit Care Med* 151: 1725–1733, 1995.
93. Schreck R, Rieber P, and Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. *EMBO J* 10: 2247–2258, 1991.
94. Schult PA, Graziano FM, and Busse WW. Enhanced eosinophil luminol-dependent chemiluminescence in allergic rhinitis. *J Allergy Clin Immunol* 77: 702–708, 1986.
95. Sedeghi–Hashjin G, Folkerts G, Henricks PA, Verheyen AK, van der Linde HJ, van Ark I, Coene A, and Nijkamp FP. Peroxynitrite induces airway hyperresponsiveness in guinea pigs *in vitro* and *in vivo*. *Am J Respir Crit Care Med* 153: 1697–1701, 1996.
96. Sedgwick JB. Mechanisms of eosinophil activation. *In* Busse WW and Holgate ST, editors. Asthma and Rhinitis. Blackwell Scientific Publications, Boston. 285–297, 1995.
97. Serra–Batlles J, Plaza V, Morejon E, Comella A, and Brugues J. Costs of asthma according to the degree of severity. *Eur Respir J* 12: 1322–1326, 1998.
98. Sies H, Sharov VS, Klotz LO, and Briviba K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite. *J Biol Chem* 272: 27812–27817, 1997.
99. Smith LJ, Houston M, and Anderson J. Increased levels of glutathione in bronchoalveolar lavage fluid from patients with asthma. *Am Rev Respir Dis* 147: 1461–1464, 1993.
100. Smith LJ, Shamsuddin M, Sporn PH, Denenberg M, and Anderson J. Reduced superoxide dismutase in lung cells of patients with asthma. *Free Radic Biol Med* 22: 1301–1307, 1997.
101. Stamler JS, Loh E, Roddy MA, Currie KE, and Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. *Circulation* 89: 2035–2040, 1994.
102. Su WY, Folz R, Chen JS, Crapo JD, and Chang LY. Extracellular superoxide dismutase mRNA expressions in the human lung by in situ hybridization. *Am J Respir Cell Mol Biol* 16: 162–170, 1997.

103. Sugiura H, Ichinose M, Oyake T, Mashito Y, Ohuchi Y, Endoh N, Miura M, Yamagata S, Koarai A, Akaike T, Maeda H, and Shirato K. Role of peroxynitrite in airway microvascular hyperpermeability during late allergic phase in guinea pigs. *Am J Respir Crit Care Med* 160: 663–671, 1999.
104. Sugiura H, Ichinose M, Tomaki M, Ogawa H, Koarai A, Kitamuro T, Komaki Y, Akita T, Nishino H, Okamoto S, Akaike T, and Hattori T. Quantitative assessment of protein-bound tyrosine nitration in airway secretions from patients with inflammatory airway disease. *Free Radic Res* 38: 49–57, 2004.
105. Sugiura H, Liu X, Kobayashi T, Togo S, Ertl RF, Kawasaki S, Kamio K, Wang XQ, Mao L, Shen L, Hogaboam CM, and Rennard SI. Reactive nitrogen species augment fibroblast-mediated collagen gel contraction, mediator production, and chemotaxis. *Am J Respir Cell Mol Biol* 34: 592–599, 2006.
106. Takahashi T, Miura M, Katsumata U, Ichinose M, Kimura K, Inoue H, Takishima T, and Shirato K. Involvement of superoxide in ozone-induced airway hyperresponsiveness in anesthetized cats. *Am Rev Respir Dis* 148: 103–106, 1993.
107. Taylor L, Menconi MJ, and Polgar P. The paticipation of hydroperoxides and oxygen radicals in the control of prostaglandin synthesis. *J Biol Chem* 258: 6855–6857, 1983.
108. Taylor SM, Pare PD, and Schellenberg RR. Cholinergic and non-adrenergic mechanisms in human and guinea pig airways. *J Appl Physiol* 56: 958–965, 1984.
109. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N, and Shirato K. Elevated substance P cocentration in sputum after hypertonic saline inhalation in asthma and chronic bronchitis patients. *Am J Respir Crit Care Med* 151: 613–617, 1995.
110. Tucker JF, Brave SR, Charalambous L, Hobbs AJ, and Gibson A. L-NG-nitro arginine inhibits non-adrenergic, non-cholinergic relaxations of guinea-pig isolated tracheal smooth muscle. *Br J Pharmacol* 100: 663–664, 1990.
111. van der Vliet A, Eiserich JP, Shigenaga MK, and Cross CE. Reactive nitrogen species and tyrosine nitration in the respiratory tract: epiphenomena or a pathobiologic mechanism of disease? *Am J Respir Crit Care Med* 160: 1–9, 1999.
112. Wen FQ, Liu X, Manda W, Terasaki Y, Kobayashi T, Abe S, Fang Q, Ertl R, Manouilova L, and Rennard SI. TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. *J Allergy Clin Immunol* 111: 1307–1318, 2003.
113. Willis D, Moore AR, Frederick R, and Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. *Nat Med* 2: 87–90, 1996.
114. Xia ZW, Zhong WW, Xu LQ, Sun JL, Shen QX, Wang JG, Shao J, Li YZ, and Yu SC. Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. *J Immunol* 177: 5936–5945, 2006.
115. Xu P, LaVallee P, and Hoidal JR. Repressed expression of the human xanthine oxidoreductase gene. E-box and TATA-like elements restrict ground state transcriptional activity. *J Biol Chem* 275: 5918–5926, 2000.
116. Yeadon M and Payne AN. Ozone induces bronchial hyperreactivity to inhaled substance P by functional inhibition of enkephalinase. *Br J Pharmacol* 99: 191P, 1990.
117. Yoshida M, Romberger DJ, Illig MG, Takizawa H, Sacco O, Spurzem JR, Sisson JH, Rennard SI, and Beckmann JD. Transforming growth factor-? stimulates the expression of desmosomal proteins in bronchial epithelial cells. *Am J Respir Cell Mol Biol* 6: 439–445, 1992.
118. Yukawa T, Read RC, Kroegel C, Rutman A, Chung KF, Wilson R, Cole PJ, and Barnes PJ. The effects of activated eosinophils and neutrophils on guinea pig airway epithelium *in vitro*. *Am J Respir Cell Mol Biol* 2: 341–353, 1990.
119. Zayasu K, Sekizawa K, Okinaga S, Yamaya M, Ohrui T, and Sasaki H. Increased carbon monoxide in exhaled air of asthmatic patients. *Am J Respir Crit Care Med* 156: 1140–1143, 1997.
120. Zhang M, Nomura A, Uchida Y, Iijima H, Sakamoto T, Iishii Y, Morishima Y, Mochizuki M, Masuyama K, Hirano K, and Sekizawa K. Ebselen suppresses late airway responses and airway inflammation in guinea pigs. *Free Radic Biol Med* 32: 454–464, 2002.

Address reprint requests to:
Masakazu Ichinose, M.D., Ph.D.
Third Department of Internal Medicine
Wakayama Medical University School of Medicine
811-1 Kimiidera
Wakayama City
Wakayama 641-0012, Japan

E-mail: masakazu@wakayama-med.ac.jp

Date of first submission to ARS Central, September 28, 2007; date of final revised submission, October 1, 2007; date of acceptance, October 14, 2007.

Nitrative stress in refractory asthma

Hisatoshi Sugiura, MD, PhD,[a] Yuichi Komaki, MD, PhD,[b] Akira Koarai, MD, PhD,[a] and Masakazu Ichinose, MD, PhD[a] *Wakayama and Sendai, Japan*

Background: Most asthma is mild and moderate and can be well controlled by low-dose inhaled steroid with or without bronchodilators. However, 5% to 10% of patients with asthma have more troublesome disease despite using such medication. Recent reports showed that nitrative stress induced tissue remodeling *in vitro*, which is associated with a component of refractoriness in asthma. However, there is no report that nitrative stress is involved in refractory asthma.
Objective: The aim of this study is to evaluate whether patients with refractory asthma have more nitrative stress.
Methods: Ten healthy subjects, 10 patients with well-controlled asthma, and 8 patients with refractory asthma took part in the current study. Exhaled nitric oxide, xanthine oxidase activity in the supernatant of the sputum, immunostaining for the inducible type of nitric oxide synthase, and 3-nitrotyrosine in induced sputum from the subjects were assessed.
Results: All nitrative markers including exhaled nitric oxide ($P < .01$), immunopositivities for inducible nitric oxide synthase ($P < .01$), xanthine oxidase activities ($P < .01$), and 3-nitrotyrosine ($P < .01$) in sputum from the refractory asthma group were enhanced compared with the well-controlled group. All these nitrative markers in the sputum had a significant negative correlation with the $\%FEV_1$ values ($P < .01$).
Conclusion: These results suggested that patients with refractory asthma have more nitrative stress in their airways compared with patients with well-controlled asthma.
(J Allergy Clin Immunol 2008;121:355-60.)

Key words: *Refractory asthma, induced sputum, steroids, nitrotyrosine, reactive oxygen species*

Asthma is a disorder characterized by chronic inflammation of the airways, airflow obstruction, and airway hyperreactivity.[1-3] Most asthma is well controlled by low doses of anti-inflammatory agents with or without bronchodilators.[4] However, 5% to 10% of patients with asthma have more troublesome disease reflected by a higher medication requirement to maintain good disease control. They have persistent symptoms, disease exacerbation, airflow obstruction, and low quality of life in spite of using bronchodilators in addition to high doses of steroids.[5] For describing this subgroup of patients with asthma with troublesome disease, the term *refractory asthma* has been used.[5] It has been reported that individuals with refractory asthma are 15 times more likely to use emergency medical care than patients with well-controlled asthma and are 20 times more likely to require hospital admission.[6] In view of the effect of refractory asthma on healthcare resources and the need to understand the mechanisms involved in refractory asthma, elucidating the pathophysiological features of refractory asthma could be important.

Abbreviations used
eNO: Exhaled nitric oxide
HDAC 2: Histone deacetylase 2
ICS: Inhaled corticosteroid
iNOS: Inducible nitric oxide synthase
NO: Nitric oxide
RNS: Reactive nitrogen species
XO: Xanthine oxidase

Recent reports showed that patients with severe asthma had more oxidative stress in their airways.[7,8] In inflammatory conditions, excessive nitric oxide (NO) derived from the inducible type of NO synthase (iNOS) was produced as well as superoxide anion from nicotinamide adenine dinucleotide (NADPH) oxidase[9] or xanthine oxidase (XO).[10] In general, NO is rapidly reacted with superoxide anion to produce the highly reactive nitrogen species (RNSs) such as peroxynitrite.[11] In addition, excessive RNSs cause tissue injury, lipid peroxidation, and nitration of tyrosine residues.[11] RNSs can also cause the inflammation in asthmatic airway[12,13] and moreover are reported to induce airway remodeling, which may be associated with a component of airflow obstruction in patients with refractory asthma,[5] mediated by fibroblasts.[14]

A recent cross-sectional, multicenter study showed that patients with more severe refractory asthma treated with oral corticosteroids had NO levels that were almost 3 times higher than those treated only with inhaled corticosteroids (ICSs),[15] suggesting that NO or NO-related molecules such as RNSs may contribute to the pathogenesis of refractory asthma. However, there is little information on nitrative stress in the airways of refractory asthma.

The aim of the current study, therefore, was to evaluate the degree of nitrative stress in refractory asthma. To accomplish this, healthy subjects, patients with well-controlled asthma, and patients with refractory asthma took part in the current study, and the nitrative stress markers including exhaled NO (eNO), iNOS expression, XO activity, and 3-nitrotyrosine formation were assessed. Furthermore, we assessed the correlation between lung function and each marker of nitrative stress.

METHODS

Subjects

Ten healthy subjects, 10 patients with well-controlled asthma, and 8 patients with refractory asthma took part in the current study. Patients with

From [a]the Third Department of Internal Medicine, Wakayama Medical University School of Medicine; and [b]the Division of Respiratory and Infectious Diseases, Tohoku University Graduate School of Medicine, Miyagi, Sendai.

Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

Received for publication October 5, 2007; revised November 10, 2007; accepted for publication November 13, 2007.

Available online January 3, 2008.

Reprint requests: Masakazu Ichinose, MD, PhD, Third Department of Internal Medicine, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama City, Wakayama 641-0012, Japan. E-mail: masakazu@wakayama-med.ac.jp.

0091-6749/$34.00

doi:10.1016/j.jaci.2007.11.009

TABLE I. Characteristics of study subjects

Subject no.	Sex	Age (y)	FVC (L)	FEV_1 (L)	FEV_1/FVC (%)	%FEV_1 (%)	Exacerbation rates (times/y)	Inhaled steroid (oral steroid)	Other medications
H-1	F	49	3.30	2.67	80.9	118			
H-2	M	21	5.01	4.21	84.0	99.0			
H-3	M	67	3.34	2.55	76.3	90.0			
H-4	F	26	3.89	3.33	85.6	116			
H-5	M	19	3.88	3.33	85.8	111			
H-6	M	60	3.81	3.00	78.7	98.0			
H-7	M	51	3.54	3.13	88.4	97.4			
H-8	F	50	3.70	3.18	85.9	100			
H-9	M	33	4.11	3.54	86.1	92.0			
H-10	M	44	4.43	3.41	77.0	110			
Mean		42.0	3.90	3.24	82.9	103			
SE		5.5	0.2	0.2	1.4	3.3			
W-1	F	35	3.36	2.76	82.1	103	0	400	
W-2	M	26	4.16	3.03	72.8	82.9	0	400	
W-3	F	30	3.62	2.54	70.2	84.4	1	400	
W-4	F	27	3.91	3.31	84.7	120	0	400	
W-5	F	65	2.24	1.62	72.3	80.3	1	400	
W-6	F	68	2.58	1.84	71.3	101	0	400	
W-7	F	49	3.04	2.33	76.6	98.0	0	400	
W-8	M	35	5.29	4.25	80.3	97.4	0	400	
W-9	M	33	4.83	3.89	80.5	103	1	400	
W-10	M	32	4.88	3.93	80.5	102	0	400	
Mean		40.0	3.79	2.95	77.1	97.2	0.3		
SE		5.1	0.3	0.3	1.7	4.0	0.2		
R-1	F	55	2.90	1.65	56.9	71.5	3	1600	LABA, T
R-2	M	53	2.49	1.63	65.5	54.0	4	1600	LABA, T, LT
R-3	F	38	3.68	2.21	60.1	76.6	2	1600 (5)	LABA, T, LT
R-4	M	35	3.57	2.37	66.4	59.6	2	1600	LABA, T
R-5	M	24	4.22	2.76	65.4	70.6	3	1600 (10)	LABA, T, LT
R-6	M	35	3.96	2.48	62.6	63.8	2	1600	LABA, T
R-7	F	32	3.65	1.88	51.5	66.2	3	1600	LABA, T, LT
R-8	F	45	3.34	1.76	52.7	73.4	2	1600 (5)	LABA, T, LT
Mean		39.6	3.48	2.09*†	60.1*‡	67.0*‡	2.6‡		
SE		3.6	0.2	0.2	2.0	2.8	0.3		

Patients with well-controlled asthma were treated with low doses of inhaled steroid (μg/d). Patients with refractory asthma were treated with bronchodilators in addition to high doses of inhaled steroid (μg/d) or high doses of inhaled steroid (μg/d) plus oral steroid (mg/d).

F, Female; *FVC*, forced vital capacity; *H*, healthy subjects; *LABA*, long-acting β-agonist; *LT*, leukotriene receptor antagonist; *M*, male; *R*, patient with refractory asthma; *T*, theophylline; *W*, patient with well-controlled asthma.

*$P < .01$ compared with values of healthy subjects group; †$P < .05$, ‡$P < .01$ compared with values of well-controlled asthma group.

asthma had their disease diagnosed on the basis of recurrent episodes of wheezing, airway reversibility by β_2-agonist, airway hyperresponsiveness, and eosinophilia as assessed by sputum examination. All subjects had never smoked and had not had a respiratory tract infection during the month preceding the test. The patients were divided into those with refractory and those with well-controlled disease according to the criteria of the American Thoracic Society Workshop.[5] Briefly, refractory asthma was not well controlled despite continuous treatment more than half the year with long-acting β-agonists, theophylline, and leukotriene antagonist in addition to more than 1260 μg/d beclomethasone dipropionate, or equivalent doses of other ICSs, or a combination of ICSs and oral corticosteroids. Because the values of FEV_1 percent predicted in all patients with refractory asthma were less than 80%, they had persistent airway obstruction (Table I). All patients with refractory asthma satisfied both the major criteria and more than 2 minor criteria, and they did not have any other diseases such as chronic obstructive pulmonary disease. Healthy subjects with normal lung function, no abnormality in chest x-ray, and no respiratory symptoms were enrolled in the current study as the healthy subjects. Inclusion in the well-controlled asthma group required that there had been no asthma exacerbation in the past year and normal lung function treated with low doses of inhaled steroid (400 μg/d). The study was conducted with the approval of the Tohoku University Committee on Clinical Investigation. Written informed consent was obtained from all subjects.

Sputum induction and processing

Sputum was induced and processed according to the method described in our previous study.[16] Briefly, after inhalation of salbutamol, the subjects inhaled 4% hypertonic saline. The sputum induction was safely performed even in the subjects with refractory asthma by treating them with salbutamol. Obtained sputum samples were treated with Sputasol (Oxoid Ltd, Basingstoke, United Kingdom) and then centrifuged at 790*g* for 10 minutes. All supernatant samples were stored at −80°C. The obtained cell pellet was resuspended and the total cell count of leukocytes was obtained, and then the cells were stained using Hansel stain (Torii Pharmaceutical, Tokyo, Japan) to assess the cell differential.

Measurement of eNO

A rapid response chemiluminescent analyzer (280NOA; Sievers Instruments Inc, Boulder, Colo) was used for the analysis of eNO.[16] The subjects expired at a constant flow rate (100 mL/min), and the eNO was measured by an online system.



FIG 1. Immunochemical detection of iNOS in induced sputum cells and exhaled NO levels in healthy subjects **(A)**, subjects with well-controlled asthma **(B)**, and subjects with refractory asthma **(C)**. **D**, The percentages of iNOS-positive cells (%) in the sputum from healthy subjects (*open bar*, n = 10), subjects with well-controlled asthma (*filled bar*, n = 10) and subjects with refractory asthma (*hatched bar*, n = 8) were counted. **E**, Exhaled NO levels (ppb) in healthy subjects (*open bar*, n = 10), subjects with well-controlled asthma (*filled bar*, n = 10) and subjects with refractory asthma (*hatched bar*, n = 8) were measured.

Immunocytostaining

Immunocytostaining for iNOS or 3-nitrotyrosine was performed as previously described.[16] In the current study, we used 3-nitrotyrosine formation as a stable marker for RNS production. Briefly, after fixation, blocking of endogenous peroxidase, and nonspecific binding of antibodies, the preparations were incubated with primary antibody (anti-iNOS rabbit antisera, 1:200 dilution; Wako Pure Chemical Industries, Osaka, Japan; or antinitrotyrosine rabbit polyclonal IgG, 1:100 dilution; Upstate Biotechnology, Lake Placid, NY). The immunoreactions were visualized by using ENVISION polymer reagent (DAKO Japan Ltd, Kyoto, Japan). The diaminobenzidine reaction was performed, followed by counterstaining with Hansel stain. Two investigators examined and counted more than 500 leukocytes and iNOS or 3-nitrotyrosine immunopositive cells without previous knowledge of the treatment. The mean values from 2 investigators were registered.

Measurement of XO activity

Xanthine oxidase activity in the supernatant of the sputum was measured according to the previous study.[12] Pterin was added to each sample as a substrate for XO. All samples were assayed for their XO activity by using a spectrofluorometer (model 650-40; Hitachi Ltd, Tokyo, Japan). The activity was expressed as the formation of isoxanthopterin.

Statistical analysis

Data were expressed as means ± SEMs. Experiments with multiple comparisons were evaluated by 1-way ANOVA followed by the Scheffé test.



FIG 2. XO activities in the supernatant of the sputum from healthy subjects, subjects with well-controlled asthma, and subjects with refractory asthma. The activities of XO (nmol isoxanthopterin/mL/h) in the supernatant of the sputum from healthy subjects (*open bar*, n = 10), subjects with well-controlled asthma (*filled bar*, n = 10), and subjects with refractory asthma (*hatched bar*, n = 8) were measured.

Pearson correlation analysis was performed to assess the correlation. Probability values of less than .05 were considered significant.

RESULTS

The values of FEV_1, FEV_1/forced vital capacity, and $\%FEV_1$ in the refractory asthma group were significantly lower than those in the healthy or well-controlled asthma groups (Table I). Exacerbations rates were more frequent in the refractory asthma group than in the well-controlled asthma group (Table I).

Cells positive for iNOS were observed mainly in neutrophils, macrophages, and eosinophils (Fig 1, *A-C*). The percentages of iNOS-positive cells in both the well-controlled (17.1 ± 3.4%; Fig 1, *D, filled bar*) and refractory asthma groups (36.6 ± 3.3%; Fig 1, *D, hatched bar*) were higher than those in the healthy group (7.5 ± 1.6%; $P < .01$; Fig 1, *D, open bar*). Moreover, there were significantly more iNOS-positive cells in the refractory asthma group than in the well-controlled asthma group ($P < .01$; Fig 1, *D*). The values of eNO in the refractory asthma group (50.9 ± 4.3 ppb; Fig 1, *E, hatched bar*) were significantly higher than in the healthy (9.1 ± 0.9 ppb; Fig 1, *E, open bar*) or well-controlled asthma groups (13.3 ± 2.5 ppb; $P < .01$; Fig 1, *E, filled bar*). The activities of XO in the sputum, which is an enzyme generating superoxide anion, in the refractory asthma group (643 ± 140 nmol isoxanthopterin/mL/h; Fig 2, *hatched bar*) were significantly higher than in the healthy (33.5 ± 5.6 isoxanthopterin/mL/h; Fig 2, *open bar*) or well-controlled asthma groups (83.0 + 16 isoxanthopterin/mL/h; $P < .01$; Fig 2, *filled bar*). 3-Nitrotyrosine positive cells were observed mainly in neutrophils, macrophages, and eosinophils. The percentages of 3-nitrotyrosine positive cells in both the well-controlled (16.6 ± 2.6%; Fig 3, *D, filled bar*) and refractory asthma groups (35.1 ± 3.5%; Fig 3, *D, hatched bar*) were higher than those in the healthy group (7.1 ± 1.6%; $P < .01$; Fig 3, *D, open bar*). Moreover, there were significantly more 3-nitrotyrosine–positive cells in the refractory asthma group than in the well-controlled asthma group ($P < .01$; Fig 3). We also investigated the correlation between the XO activities or iNOS expression and 3-nitrotyrosine formation. There were significantly positive correlations between 3-nitrotyrosine–



FIG 3. Immunochemical detection of 3-nitrotyrosine of induced sputum cells. Preparations of sputum from healthy subjects **(A)**, subjects with well-controlled asthma **(B)**, and subjects with refractory asthma **(C)** were stained with antinitrotyrosine antibody. **D**, The percentage of 3-nitrotyrosine–positive cells (%) in the sputum from healthy subjects (*open bar*, n = 10), subjects with well-controlled asthma (*filled bar*, n = 10), and subjects with refractory asthma (*hatched bar*, n = 8) were counted. *NT*, 3-Nitrotyrosine.



FIG 4. Correlation between values of 3-nitrotyrosine–positive cells and values of XO activities or iNOS-positive cells in sputum from subjects with asthma. Correlations between the values of 3-nitrotyrosine–positive cells and XO activities **(A)** or iNOS-positive cells **(B)** from all patients with asthma were analyzed (*open circles*, subjects with well-controlled asthma; *closed circles*, subjects with refractory asthma). *r* values were Pearson correlation coefficients. *NT*, 3-Nitrotyrosine.



FIG 5. Correlation between airway caliber and each marker of oxidative/nitrative stress in subjects with asthma. Correlation between $\%FEV_1$ values and values of exhaled NO **(A)**, activities of XO **(B)**, iNOS-positive cells **(C)**, or 3-nitrotyrosine–positive cells **(D)** was analyzed (*open circles*, subjects with well-controlled asthma; *closed circles*, subjects with refractory asthma). *r* values were Pearson correlation coefficients. *NT*, 3-Nitrotyrosine.

positive cells and XO activities ($r = 0.86$; $P < .01$; Fig 4, *A*) or iNOS-positive cells ($r = 0.97$; $P < .01$; Fig 4, *B*). Each parameter of eNO ($r = -0.74$; $P < .01$), XO activities of sputum ($r = -0.78$; $P < .01$), percentage of iNOS-positive cells ($r = -0.79$; $P < .01$), and 3-nitrotyrosine–positive cells ($r = -0.76$; $P < .01$) had a significantly negative correlation with $\%FEV_1$ (Fig 5). Sputum neutrophils in the refractory asthma group (22.5 + 2.4%) were significantly higher than those in the healthy (13.0 ± 1.3%; $P < .01$) or well-controlled asthmatic groups (13.7 ± 1.0%; $P < .01$; Table II). The eosinophil counts in the well-controlled ($P < .01$) or refractory asthmatic groups ($P < .01$) were significantly increased compared with those in the healthy group. The eosinophil counts in refractory asthma group had a tendency to increase compared with those in the well-controlled group; however, there was no significant difference between the 2 groups (Table II).

DISCUSSION

Although the patients with refractory asthma have high medication requirements to maintain good disease control, they had an airflow obstruction or low quality of life despite treatment with high doses of steroids.[5] Such patients have a disproportionate effect on healthcare utilization, accounting for at least half of the direct and indirect costs of treating asthma.[6] In view of the effect of refractory asthma on healthcare resources, it is important to clarify the mechanisms involved in refractory asthma.

To explore the mechanisms underlying refractory asthma, we investigated the degree of nitrative stress between refractory asthma and well-controlled asthma because RNSs induce airway inflammation[12] and remodeling.[13] We demonstrated that patients with refractory asthma had more nitrative stress compared with patients with well-controlled asthma. Nitrative stress has been reported to stimulate the production of proinflammatory cytokines, adhesion molecule expression, and chemokine production through the stimulation of transcription factors including NF-κB and activator protein-1.[17,18] Furthermore, it has been reported that RNSs had inflammatory effects on the airways of asthmatic models,[12] and RNSs caused airway hyperresponsiveness.[19,20] These findings suggested that excessive RNSs could play a role in the pathogenesis of refractory asthma.

Many patients with refractory asthma have impaired lung function. Such an impairment is associated with a component of airflow obstruction that appears either irreversible or, at best, difficult to reverse. This irreversible airflow limitation in patients with asthma has been reported to be associated with airway remodeling.[5] Recently, we reported that peroxynitrite, one of the RNSs, enhanced fibroblast-mediated collagen gel contraction and chemotaxis toward fibronectin *in vitro*.[13] We also reported that peroxynitrite stimulated fibroblast-mediated mediator production including TGF-β_1, fibronectin, and vascular endothelial

TABLE II. Cell differential counts of sputum in study subjects

	Total cell number (10^4 cells/mL)	Neutrophil (%)	Macrophage (%)	Eosinophil (%)	Lymphocyte (%)
Healthy subjects	95.9 ± 26	13.7 ± 1.0	78.2 ± 2.0	1.0 ± 0.3	7.1 ± 1.2
Well-controlled asthma	176 ± 60	13.0 ± 1.3	71.6 ± 2.0	7.5 ± 1.9*	7.9 ± 1.0
Refractory asthma	201 ± 54	22.5 ± 2.4*‡	61.1 ± 2.1*†	10.0 ± 1.9*	6.4 ± 1.0

*$P < .01$ compared with values of healthy subjects group; †$P < .05$, ‡$P < .01$ compared with values of well-controlled asthma group.

growth factor, which are key mediators responsible for airway remodeling.[13] In the current study, we did not perform the airway reversibility test using a short-acting β-agonist or airway tissue examination by bronchial biopsy. Therefore, it was unclear whether airway remodeling occurred in the airways of the subjects with refractory asthma. However, each parameter of exhaled NO, XO activities, iNOS-positive cells, or 3-nitrotyrosine positive cells was significantly correlated with the airway caliber, suggesting that RNS-mediated mechanisms may be related to the airway narrowing of patients with asthma.

In the current study, a good correlation between 3-nitrotyrosine–positive cells and XO activities or iNOS-positive cells in sputum from all patients with asthma was observed. 3-Nitrotyrosine is a footprint of RNS production. A free amino acid form of tyrosine or tyrosine residues of proteins is nitrated by peroxynitrite[11] or via the H_2O_2/ peroxidase-dependent nitrite oxidation pathway.[21] As shown in Fig 4, there was very good correlation ($r = 0.97$) between 3-nitrotyrosine–positive cells and iNOS-positive cells, suggesting that iNOS might be responsible for the RNS production observed in the current study. Also, there was a positive correlation between 3-nirotyrosine–positive cells and XO activities. We previously reported that the XO inhibitor allopurinol reduced 3-nitrotyrosine–positive cell counts in sputum from patients with chronic obstructive pulmonary disease,[22] suggesting that superoxide anion derived from XO might be responsible for RNS production in the airways of inflammatory lung diseases. Taken together, both iNOS and XO may be associated with the generation of RNSs in the airways of patients with asthma.

Steroids have a number of anti-inflammatory actions including the suppression of iNOS expression.[23,24] In the current study, steroids were not enough to suppress iNOS expression and 3-nitrotyrosine production completely in the sputum from patients with refractory asthma even at high doses. Recently, Ito et al[25] reported that peroxynitrite reduced the histone deacetylase 2 (HDAC 2) activity in epithelial cells through the nitration of tyrosine residues in HDAC 2. A reduction of HDAC 2 activity could contribute to the worsening of inflammation through the excessive production of proinflammatory cytokines including IL-1β and IL-8.[25] They also showed that the HDAC 2 activity was decreased in patients with asthma and patients with COPD.[26] Inhibition of HDAC 2 was reported to interfere with glucocorticoid receptor–activated transcription.[27] It may be possible that inactivation of HDAC 2 by excessive RNSs occurs in refractory asthma.

There was a significant increase of neutrophils in the sputum from patients with refractory asthma compared with patients with well-controlled asthma. Our results are compatible with a previous multicenter study.[15] Although the precise mechanisms responsible for the increased neutrophilia in refractory asthma are still uncertain, there are a few possibilities. First, RNSs can stimulate airway IL-8 production, which is a potent chemoattractant for neutrophils,[26,28] and this may account for the increased neutrophilia in the airways of refractory asthma. Second, steroids are reported to inhibit the apoptosis of neutrophils.[29] These mechanisms may contribute to the neutrophilia in refractory asthmatic airways. In the current study, there was no statistically significant increase of eosinophils in the sputum from patients with refractory asthma compared with patients with well-controlled asthma, as shown in Table II. It remains controversial whether neutrophilic[15] or persistent eosinophilic inflammation[30] occurs in the airways of refractory asthma, and further study is needed to clarify this issue.

A limitation of the current study is that the cellular expression of iNOS and the formation of 3-nitrotyrosine were only investigated in leukocytes of the sputum. In the airways of patients with asthma, many types of cells including bronchial epithelial cells, endothelial cells, and neurons express nitric oxide synthase.[31] Especially bronchial epithelial cells have been reported to express iNOS strongly and to be one of the main sources of RNSs.[31] However, the bronchial epithelial cells in the sputum were very scarce (less than 1%) in the current study, which is compatible with a previous report.[32] Furthermore, it was hard to analyze the staining in the bronchial epithelial cells because most part of the cells were overlapped on the preparation. Thus, bronchoscopic biopsies of the airway are needed to assess the degree of nitrative stress in the bronchial epithelial cells precisely.

In summary, our data demonstrate that iNOS-positive cells, eNO, XO activities, and 3-nitrotyrsine–positive cells were significantly increased in refractory asthma compared with well-controlled asthma. Each parameter of iNOS-positive cells, eNO, XO activities, 3-nitrotyrsine positive–cells, and neutrophils in sputum had a significant negative correlation with the airway caliber. Because RNSs have inflammatory and remodeling actions in tissues, these mediators may be related to the refractoriness of asthma. Further study is needed to clarify the precise mechanisms. Specific inhibitors or scavengers of RNSs may become a therapeutic target for refractory asthma.

We thank Dr M. Tomaki and H. Ogawa for discussions on the current study. We thank Dr G. Tamura for recruiting patients with asthma into the current study. We also thank Mr B. Bell for reading the manuscript.

Clinical implications: More nitrative stress could be involved in the refractoriness of bronchial asthma.

REFERENCES

1. Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OP, Howarth PH, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-57.
2. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999;104:1001-6.